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Background: Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine
kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung
cancer (NSCLC). We investigated whether crizotinib could influence heart rate (HR) through direct cardiac effects.
Methods: The direct effect of crizotinib on HR was studied using ECG analysis of Langendorff-perfused mouse
hearts. The whole-cell patch clamp technique was used to measure the effects of crizotinib on the hyperpolarization-
activated funny current, If, in mouse sinoatrial node cells (SANCs) and hyperpolarization-activated cyclic nucleotide-
gated channel 4 (HCN4) activity in HEK-293 cells stably expressing human HCN4.
Results: Crizotinib resulted in a dose-dependent reduction in HR in isolated intact mouse hearts with a half maximal
inhibitory concentration (IC50) of 1.7 ± 0.4 μmol/L. Because ECG analysis revealed that crizotinib (0–5 μmol/L) resulted
in significant reductions in HR in isolated mouse hearts without changes in PR, QRS, or QT intervals, we performed
whole-cell patch clamp recordings of SANCs which showed that crizotinib inhibited If which regulates cardiac
pacemaker activity. Crizotinib resulted in diminished current density of HCN4, the major molecular determinant
of If, with an IC50 of 1.4 ± 0.3 μmol/L. Crizotinib also slowed HCN4 activation and shifted the activation curve to the left
towards more hyperpolarized potentials.
Conclusions: Our results suggest that crizotinib’s effects on HCN4 channels play a significant role in mediating its
observed effects on HR.
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Crizotinib is a first-in-class, orally available multi-
targeted receptor tyrosine kinase (RTK) inhibitor for the
treatment of anaplastic lymphoma kinase (ALK)-rear-
ranged non-small cell lung cancer (NSCLC) that is
locally advanced or metastatic [1]. In addition, crizotinib
has demonstrated clinical activity in mesenchymal epi-
thelial transition (MET) and ROS1-rearranged NSCLC
and will likely play an expanding role in targeted therapy
for NSCLC [2]. We previously identified asymptomatic
marked sinus bradycardia (defined as heart rate ≤ 45) in* Correspondence: stibe001@mc.duke.edu
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evidence of prolongation of PR or QT intervals [3]. Sub-
sequently, we performed a retrospective analysis of 42
patients with NSCLC who were treated with crizotinib
in clinical trials and found that a decrease in heart rate
(HR) was common among patients treated with crizo-
tinib [4]. Recently, a large retrospective analysis of HR
changes during crizotinib therapy among patients with
ALK‐positive NSCLC enrolled in the PROFILE 1005 and
PROFILE 1007 clinical trials was analyzed [5]. For the
1053 patients analyzed, the mean maximum post-
baseline HR decrease was 25 beats per minute (bpm)
[5]. Overall, 441 patients (41.9%) had at least one
episode of post-baseline sinus bradycardia (defined as
HR < 60 bpm). The likelihood of experiencing sinusle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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patients with a pre-crizotinib treatment HR <70 bpm
[5]. In another study, the effect of crizotinib on HR was
also found to be serum concentration-dependent with
an average 2.5 bpm decrease in HR for every 100 ng/mL
increase of serum crizotinib concentration without clin-
ically or statistically significant QT prolongation [6].
Although a decrease in HR is frequently observed in
patients treated with crizotinib [5], the mechanism of
the observed reduction in HR is unknown. It is also un-
clear if the decrease in HR is a direct cardiac effect since
other indirect factors such as metabolic hormones and
neurohormonal activity can have significant effects on
HR, and crizotinib has been associated with endocrine
effects such as lowering of testosterone levels in men
[7, 8]. We, therefore, investigated whether crizotinib
could influence HR through direct cardiac effects
using a combination of approaches involving intact
mouse heart physiology and cellular electrophysiology.
Methods
ECG analysis of Langendorff-perfused mouse hearts
Experiments involving mice were performed according
to NIH policies outlined in the Guide for Care and Use
of Laboratory Animals. Protocols for animal research
were reviewed by the Institutional Animal Care and Use
Committee of Duke University Medical Center. C57BL/
6 J mice were obtained from The Jackson Laboratory
(Bar Harbor, ME). Mice were anesthetized with isoflur-
ane inhalation. After a surgical level of anesthesia was
confirmed, a thoracotomy was performed and the heart
removed quickly. Hearts were isolated in ice cold buffer
and retrograde perfused in a Langendorff perfusion sys-
tem with Krebs-Henseleit buffer, which contained (in
mmol/L): NaCl 118, KCl 4.7, CaCl2 2.0, MgSO4 1.2, Na-
EDTA 0.5, NaHCO3 25, KH2PO4 1.2, and glucose 11,
and equilibrated with a mixed 95% O2 and 5% CO2. The
procedure was completed within 2 minutes. Then the
heart was placed in a small cradle filled with perfusion
buffer. Four wire electrodes were positioned around the
heart cradle in an approximated Einthoven configur-
ation for recording of ECG signals, as previously de-
scribed [9]. The heart was perfused with a constant
flow rate of 2 ml/min at 37o C. After stabilization for
about 30 min, continuous ECG signals were recorded
and analyzed with LabChart7 (ADInstruments Inc.,
Colorado Springs, CO) connected with an Oct Bio
Amp and Power Lab 16/30 Data Acquisition System
(AD Instruments Inc.). Crizotinib (0–5 μmol/L) was
added to the perfusate and isolated hearts were
allowed to equilibrate for 10–15 min after each
change in crizotinib concentration. ECG parameters
(PR, QRS and QT intervals) were measured as previ-
ously described [10]. QT intervals were shown, ratherthan the corrected QT interval (QTC), as changes in
QTC reflected differences in heart rate rather than
changes in ventricular depolarization/repolarization. For
example, using the formula QTC =QT/(RR/100) 1/2 de-
scribed for correcting QT intervals in mice [10], crizotinib
(1 μmol/L) would result in a 28 ± 5% reduction in the
QTC compared with untreated controls due to the in-
crease in RR interval from 184 ± 5 to 378 ± 29 msec
(reflecting a decrease in HR), even with no significant
change in the QT interval (62.4 ± 2.6 vs. 64.3 ± 4.6 msec,
control vs. crizotinib treated).
Cell culture and immunoblotting
HEK-293 cells were obtained from ATCC (Manassas,
VA) and were grown in Dulbecco’s modified media
(DMEM) (Thermo Fisher, Waltham, MA) supplemented
with 10% fetal bovine serum (Sigma, St. Louis, MO) and
100 IU/ml penicillin and 100 μg/ml streptomycin
(Thermo Fisher). For creation of stable cell lines ex-
pressing human HCN4, HEK-293 cells were transfected
using Fugene HD reagent (Promega, Madison, WI) with
human HCN4/pcDNA3 plasmid [11, 12] linearized with
the restriction enzyme Pvu I. Transfected cells were then
maintained in selection media containing 0.4 mg/
ml G418 (Thermo Fisher) to select for the transfected
cell population. After 3–4 weeks of selection, individual
clones were picked and maintained in G418 containing
media. To confirm expression of HCN4 on a protein
level, protein lysates from non-transfected control HEK-
293 cells and HEK-293 cells with stable expression of
human HCN4 were subjected to sequential immunoblot-
ting for HCN4 and then tubulin. Rabbit anti-HCN4 IgG
was obtained from EMD Millipore (Billerica, MA) and
mouse anti-alpha-tubulin IgG was obtained from the
Developmental Studies Hybridoma Bank at the Univer-
sity of Iowa (Iowa City, IA).
Sinoatrial node (SAN) cell isolation
SAN cells were isolated as previously described [13].
The heart was excised quickly from a euthanized mouse
and immersed into oxygenated Tyrode’s solution con-
taining (in mmol/L): NaCl 140, KCl 5.4, MgCl2 1.0,
NaH2PO4 0.33, CaCl2 1.8, HEPES 5, and Glucose 10, at
pH 7.4. To isolate single SANCs, the SAN was dissected
out from surrounding atrial tissues and cut into several
small pieces. The SAN was then enzymatically digested
in Ca2+-free Tyrode’s solution containing BSA 0.2%,
Type II Collagenase (Worthington, Lakewood, NJ)
0.25 mg/mL, and Elastase (Worthington) 0.2 mg/mL.
The digestion step was carried out in a shaking incuba-
tor at 37 °C. The single SAN cells were released in modi-
fied Kraft-Brühe (KB) solution by gentle titration with a
glass transfer pipette. KB solution included (in mmol/L):
KCl 85, Potassium glutamate 20, KH2PO4 20, Taurine
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Pyruvic acid 5, MgSO4 5, and HEPES 5, at pH 7.2. The
isolated SANCs were stored in KB solution at 4 °C for at
least 2 h before experiments. Those SANCs having a
spindle-like shape and showing funny currents, If, were
chosen for patch clamp experiments.
Cellular electrophysiology
Whole-cell patch clamp recordings of funny current, If,
and HCN4 currents were performed with a MultiClamp-
700A amplifier, as described previously [13]. The cur-
rents were filtered at 2 kHz and sampled at a rate of
10 kHz. All experiments were carried out at room
temperature, unless otherwise specified. Data were
acquired and analyzed with pCLAMP software (Axon In-
struments). Correction for liquid junction potentials was
performed [14]. For funny current (If ) recording, single
SAN cells were perfused with Tyrode’s solution containing
1 mmol/L BaCl2 and 2 mmol/L MnCl2 to block the in-
ward rectifier (IKir) and ICa currents. 4-Aminopyridine
(2 mmol/L) was added to inhibit the endogenous transient
potassium current (Ito), which can overlap with and
obscure If tail current recorded at +20 mV. The pipettes
had resistances of 4–5 MΩ for experiments with SANCs
and 2–4 MΩ for experiments with HEK-293 cells when
filled with pipette solution containing (in mmol/L): 135
Potassium aspartate, 1 MgCl2, 1 CaCl2, 4 Mg-ATP,
0.4GTP, 6.6 Na2 phosphocreatine, 10 HEPES, and 10
EGTA with pH 7.2 (with KOH). The cell membrane
potential was held at -35 mV, and If was elicited by a
test pulse of −115 mV (2 s) from holding potential
every 15 s. The cell membrane capacitance was moni-
tored by a 10 msec voltage step of −10 mV from
holding potential of −35 mV.
For HCN4 current (IHCN4) recordings in stably trans-
fected HCN4-expressing HEK-293 cells, external solu-
tion was used containing (in mmol/L): NaCl 120, KCl
30, MgCl2 1.0, CaCl2 1.8, HEPES 5, and Glucose 5, with
pH 7.4 (with NaOH), in which 1 mmol/L BaCl2 and
2 mmol/L 4-Aminopyridine were added to block IKir,
and inhibit endogenous Ito. The cell membrane was held
at -10 mV. HCN4 current was then elicited by 15 s test
pulses from −65 to -135 mV in 10 mV increments then
back to +20 mV for 2 s to test tail current [15]. The cells
were perfused with crizotinib (PF-02341066, Selleck-
chem, Houston, TX) which was then washed out. To
control for potential effects of If/IHCN4 run-down over
time, the current recordings after washout were com-
pared with those before and during crizotinib exposure.
If/IHCN4 current amplitudes were determined by meas-
uring the time-dependent inward currents that were sen-
sitive to blockade with 2 mmol/L CsCl. The activation
curve for IHCN4 was constructed on the relative mem-
brane conductance by plotting normalized peak tailcurrent amplitudes against the potential of test hyperpo-
larization, and then fit with a Boltzmann equation, as pre-
viously described [16]. Activation time constants were
calculated by fitting experimental traces according to the
single-exponential equation: If = A exp (−(t-t0)/Tau), where
A is a fixed factor, t is the time, and t0 sets the onset of
current activation-deactivation.
Statistical analysis
Data are presented as means ± standard errors of the
means. A Student’s t test was used for comparison of
two groups, and a paired Student’s t test was used for
comparisons before and after crizotinib exposure. Values
of p of < 0.05 were considered significant.
Results
Crizotinib results in a dose dependent decrease in HR
Mouse hearts were isolated and perfused as described in
Methods in order to determine the direct effect of crizo-
tinib on HR: excluding potential indirect cardiac effects
that could be seen in an intact animal such as those
mediated by metabolic hormones or neurohormonal
activation. Increasing concentrations of crizotinib re-
sulted in a dose-dependent decrease in HR as assessed
by ECG analysis (Fig. 1a-b). This suggested that crizo-
tinib had a direct effect on HR since potential indirect
effects were eliminated by our isolated heart preparation.
At high concentrations of crizotinib (≥10 μmol/L), we
frequently observed high-degree AV block with persistent
atrial activity (Fig. 1c), so concentrations (≥10 μmol/L)
which were well above the range of clinically relevant
concentrations, were not included in our subsequent
analysis of ECG parameters. Crizotinib had a signifi-
cant effect on HR at concentrations ≥ 0.5 μmol/L
(Fig. 2a). The ECG parameters of PR interval (onset
of atrial depolarization to onset of ventricular
depolarization), QRS duration (duration of ventricular
depolarization), and QT interval (duration of ventricular
depolarization and repolarization) were observed over a
range of physiologically relevant crizotinib concentrations
0–5 μmol/L, and no significant effects were observed
(Fig. 2b-d). The half maximal inhibitory concentration
(IC50) of crizotinib on HR was observed to be 1.7 ±
0.4 μmol/L (Fig. 2e). Because ECG analysis of isolated
mouse hearts revealed that crizotinib (at concentrations ≤
5 μmol/L) resulted in a decrease in HR in isolated intact
mouse hearts without changes in PR, QRS, or QTC inter-
vals, similar to as observed in human subjects [4, 6], we in-
vestigated whether crizotinib exerted its effects on HR
through inhibition of the hyperpolarization-activated funny
current, If, in sinoatrial node cells (SANCs) which regulates
cardiac pacemaker activity and thus HR. Ivabradine, a
known inhibitor of the hyperpolarization-activated funny
current, If, at a concentration of 3 μmol/L which
Fig. 1 ECGs of isolated mouse hearts before and after crizotinib.
a Representative ECG tracing, as described in Methods, recorded
from an isolated mouse heart prior to exposure to crizotinib. RR
and QT intervals are indicated as shown, and time is shown on
x axis. (Note: time scale = 0–2000 msec for panels a-b and 0–10 s
for panel c). b-c Representative ECG tracings recorded from the
same isolated mouse heart as in (a) when exposed to 1 μmol/L
(b) and 10 μmol/L crizotinib (c) respectively
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sulted in a similar reduction in heart rate in our isolated
heart model as crizotinib (1 μmol/L). The addition of crizo-
tinib (1 μmol/L) in the presence of ivabradine (3 μmol/L)resulted in an additive effect on reduction of heart rate
compared with ivabradine alone (Fig. 2f).
Crizotinib inhibits funny current in isolated mouse
sinoatrial node cells
We then investigated directly whether crizotinib could
inhibit If in SANCs which regulates cardiac pacemaker
activity and HR. The whole-cell patch clamp technique
was used to measure If in mouse SANCs as described in
Methods. Crizotinib (1 μmol/L) inhibited If which then
returned to its pre-treatment level after crizotinib washout
(Fig. 3a-b). Cesium chloride (CsCl, 2 mmol/L) resulted in
complete inhibition of channel activity consistent with
what would be expected for If (Fig. 3a-b). To eliminate
potential confounding effects of If run-down over time,
the current recordings after crizotinib washout were com-
pared with those before crizotinib exposure and did not
differ significantly (Fig. 3a-b). If current density after treat-
ment with crizotinib (1 μmol/L) was 53 ± 5% that of con-
trol (Fig. 3c) (n = 6 for each group; *, p < 0.05).
Crizotinib inhibits hyperpolarization-activated cyclic
nucleotide-gated channel 4 (HCN4) activity
The molecular determinants for If are hyperpolarization-
activated cyclic nucleotide-gated channels (HCNs) of
which HCN4 is the predominant isoform in the sino-
atrial node [18]. To avoid confounding effects of mul-
tiple ionic currents found in SANCs, we studied the
effect of crizotinib on HCN4 activity using the whole-
cell patch clamp technique in HEK-293 cells stably
expressing human HCN4, as confirmed by immunoblot-
ting (Fig. 4a). Crizotinib (1 μM) resulted in a significant
decrease in HCN4 activity compared with pre-treatment
control (Fig. 4b). As with measurements of If, we com-
pared current recordings after crizotinib washout with
those prior to crizotinib exposure to eliminate potential
confounding effects of IHCN4 run-down over time and
saw no significant change (not shown). Comparison of
the current–voltage (I-V) relationship after crizotinib
washout with that during crizotinib exposure showed a
significant reduction in HCN4 current density with cri-
zotinib exposure over a range of test potentials from
−65 mV to −135 mV (*, p < 0.05, washout vs. crizotinib
treated I-V curves by two-way ANOVA) (Fig. 4c). At a
test potential of −115 mV, crizotinib (1 μmol/L) resulted
in a 40 ± 11% reduction in HCN4 current density
(Fig. 4c). Crizotinib shifted the activation curve to the
left towards more hyperpolarized potentials and shifted
the average activation midpoint (V0.5, the voltage at
which the tail current amplitude reached half maximal
activation) from −84 ± 2 to −102 ± 2 mV (*, washout vs.
crizotinib, p < 0.05) (Fig. 4d). In addition to affecting the
voltage-dependence of HCN4 activation, crizotinib also
affected the activation kinetics. Calculation of the
Fig. 2 Effects of crizotinib on ECG parameters in isolated mouse hearts. a Isolated mouse hearts were exposed to increasing concentrations of
crizotinib as shown (0 – 5 μmol/L, n = 6-11 for each concentration) and HR was measured by ECG. A significant reduction in HR was observed with
increasing concentrations of crizotinib (*, compared with preceding concentration, p < 0.001). b-d Isolated mouse hearts were exposed to increasing
concentrations of crizotinib (0–5 μmol/L, n = 6-11 for each concentration), and the following ECG parameters were measured as described in Methods:
PR interval (b) QRS interval (c) and QT interval (d). e Dose–response curve showing effect of crizotinib on HR (expressed as % of unstimulated control)
over a range of crizotinib concentrations (0–10 μmol/L, n = 6-11 for each concentration). The half maximal inhibitory concentration (IC50) of crizotinib
on HR was observed to be 1.7 ± 0.4 μmol/L. f HR was measured by ECG in isolated mouse hearts under basal conditions (control, white bar) and
following exposure to crizotinib (1 μmol/L, light grey bar, n = 11), ivabradine (3 μmol/L, dark grey bar, n = 5), or ivabradine plus crizotinib (3 μmol/L
and 1 μmol/L respectively, black bar, n = 5). A significant reduction in HR was observed with either crizotinib or ivabradine (*, compared with CTL,
p < 0.001) and with ivabradine plus crizotinib compared with ivabradine alone (#, compared with ivabradine alone, p < 0.001)
Fig. 3 Crizotinib inhibits funny current (If) in mouse sinoatrial node cells. The whole-cell patch clamp technique was used to measure the effects
of crizotinib on If in isolated mouse sinoatrial node cells. a Representative tracing showing steady-state If over time (min) before (a) and during
(b) perfusion of crizotinib (crizo, 1 μmol/L), after washout of crizotinib (c) and after addition of 2 mmol/L CsCl (d). Cell membrane potential was
held at -35 mV, and If was elicited by a step to -115 mV for 2 s then return to holding potential (inset, panel b). Currents were normalized to
membrane capacitance (pA/pF). b Representative single If tracings before (CTL), during perfusion with crizotinib (crizo), after washout of crizotinib
(washout), and after addition of 2 mmol/L CsCl (Cs), corresponding to a-d in panel A. c Group mean values of If current expressed as % of control
before (CTL) and after crizotinib (crizo, 1 μmol/L) (n = 6 for each group, *, p < 0.05)
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Fig. 4 Crizotinib inhibits HCN4 channel activity. a Protein lysates from non-transfected control HEK-293 cells (CTL) and HEK-293 cells with stable
expression of human HCN4 (HCN4) were subjected to sequential immunoblotting (IB) for HCN4 and then tubulin, as indicated. The whole cell
patch-clamp technique was then used to assess HCN4 channel activity in HEK-293 cells with stable expression of human HCN4. b Representative
traces of IHCN4 recorded in HCN4-expressing HEK-293 cells before (CTL) and during perfusion with crizotinib (crizo,1 μmol/L). IHCN4 was elicited
by 15 s test pulses from a holding potential of -10 mV to test potentials ranging from −65 to -135 mV (in 10 mV increments) and then back to
+20 mV for 2 s to test tail current, followed by return to holding potential (inset). c, Current–voltage (I-V) relationship for IHCN4 with crizotinib
perfusion (crizo, filled circles) and after washout (open circles) (n = 9 per group). Current shown was normalized to membrane capacitance (pA/pF).
A significant reduction in HCN4 current density was noted with crizotinib exposure at test potentials from −65 mv to −135 mV (p < 0.05,
washout vs. crizotinib treated I-V curves by two-way ANOVA). d Effect of crizotinib on the voltage dependence of HCN4 activation. Activation
curves were generated for IHCN4 with crizotinib perfusion (crizo, filled circles) and after washout (open circles). Crizotinib shifted the activation curve
to the left towards more hyperpolarized potentials and shifted the average activation midpoint (V0.5) (V0.5 = −84 ± 2 vs. -102 ± 2 mV, washout vs. crizo,
p < 0.05). e Average time constants (Tau) of HCN4 channel activation are plotted against test potentials with crizotinib perfusion (filled bars) and after
washout (open bars) (n = 11 for each group). Crizotinib resulted in slower HCN4 channel activation at test potentials≥−115 mV (*, washout vs.
crizo, p < 0.05). f IHCN4 (normalized to untreated controls) was measured at increasing crizotinib concentrations (0–10 μmol/L) in HCN4-expressing
HEK-293 cells. A smooth curve was obtained by fitting the data with the Hill equation. Half-maximal inhibition concentration (IC50) was 1.4 ± 0.3 μmol/L
(n= 4–18 at each concentration)
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vealed that crizotinib resulted in slower HCN4 channel
activation at test potentials ≥ −115 mV (*, washout vs.
crizo, p < 0.05) (Fig. 4e). The half-maximal inhibitory
concentration (IC50) of crizotinib on HCN4 activity was
1.4 ± 0.3 μmol/L (n = 4-18 at each dose) (Fig. 4f ).
Discussion
Although we found that crizotinib inhibits HCN4
channel activity, it is a non-selective channel inhibitor
[19, 20]. At high doses of crizotinib (≥10 μmol/L) we fre-
quently observed high-degree AV block with persistent
atrial activity (Fig. 1c) as has been observed in an indu-
cible cardiac-specific HCN4 knockout mouse model
[21], likely representing effects of crizotinib inhibition
on HCN4 activity in the atrioventricular node and/or
effects on other, perhaps multiple, cardiac channels.Because we chose to focus only on HCN4, the predom-
inant HCN isoform in the SAN [18], we cannot rule-out
the possibility that crizotinib may have differential ef-
fects on other HCN isoforms. Crizotinib has also been
shown to inhibit cardiac delayed rectifier potassium
current (IKr), coded by the human ether-a-go-go-related
gene (hERG) channel and has been shown to result in
QT prolongation in isolated rabbit hearts at doses ≥
10 μmol/L [19, 20]. We did not observe QT prolonga-
tion in our isolated mouse hearts likely due to the lower
concentrations of crizotinib used in our studies as well
as possible species differences. IKr is not prominent in
adult mouse ventricular cardiomyocytes which limits the
relevance of the mouse model for studying effects of
crizotinib on QT prolongation in humans [22, 23].
Crizotinib has also been shown to inhibit CaV1.2 (IC50 =
3.5 μmol/L) and NaV1.5 channels (IC50 = 3.1 μmol/L)
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cardiac effects of crizotinib including its effects on HR are
likely to represent effects on multiple cardiac ion
channels.
The half maximal inhibitory concentration that we
observed for HCN4 channels matches the IC50 that we
observed for heart rate in our isolated heart prepara-
tions, suggesting that crizotinib’s effects on HCN4 chan-
nels contribute to its effects on HR. Moreover, the
observed IC50 for crizotinib’s effects on HCN4 activity
overlaps with the range of crizotinib plasma concentra-
tions observed in patients [24]. Although human phar-
macokinetic data have shown a maximum observed
concentration, Cmax, of 65.5 ng/ml (~0.2 μmol/L) after a
single 150 mg dose of crizotinib [25], steady state trough
concentrations of crizotinib were found to range
between 100–500 ng/ml (~0.2-1.1 μmol/L) for most
patients treated with the typical crizotinib dose of
250 mg twice a day [2] and have been observed to be
considerably higher in some patients [24, 26]. Thus, the
crizotinib concentrations that we observed to have an
inhibitory effect of HCN4 activity are clinically relevant.
That a high percentage (~90%) of crizotinib is bound to
plasma proteins [27], reducing free drug concentration,
may explain why effects of crizotinib on HR are seen
only in a subset of patients and are generally well toler-
ated [5].
The mechanism by which crizotinib inhibits HCN4
channels is beyond the scope of the current work but
could involve either direct channel effects or indirect
effects through crizotinib’s effects on multiple tyrosine
kinases. Genistein, a tyrosine kinase inhibitor, was previ-
ously shown to inhibit If through a direct channel inter-
action [28]. Alternative possibilities include indirect
effects of RTK inhibition such as potential inhibition of
Src kinase activity by crizotinib, as Src tyrosine kinase
can enhance HCN4 channel activity by directly phos-
phorylating the channel protein [15, 29]. That the brady-
cardia observed in patients treated with crizotinib,
although generally asymptomatic, can be explained by a
direct cardiac effect has important implications for pa-
tient safety. The current findings provide further justifi-
cation for previous recommendations for patients to be
monitored for the development of bradycardia while on
crizotinib and for physicians to avoid concomitant use of
common medications that can cause HR lowering and
could potentially worsen the severity of bradycardia,
such as beta-blockers and calcium channel blockers,
during the course of crizotinib treatment [3, 4].
Conclusions
We found that crizotinib results in a dose-dependent re-
duction in heart rate in isolated mouse hearts suggesting
that crizotinib treatment results in sinus bradycardiathrough direct cardiac effects. We observed no signifi-
cant changes in PR, QRS and QT intervals at doses
which resulted in significant decreases in HR in isolated
heart preparations. This suggested that crizotinib may
result in a reduction in heart rate through effects on car-
diac pacemaker activity. We then tested the effects of
crizotinib in cardiac pacemaker cells of the SA node and
found a significant reduction in If responsible for dia-
stolic depolarization and spontaneous activity of these
cells. Furthermore, crizotinib significantly inhibited
HCN4 channel activity, the major molecular determin-
ant of If. Our results suggest that crizotinib’s effects on
HCN4 channels play a significant role in mediating its
observed effects on HR.
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